Setidegrasib results published in New England Journal of Medicine FORT MYERS, Fla., April 2, 2026 /PRNewswire/ -- Results of a Phase 1 clinical study conducted with participation from Florida Cancer ...
New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...
The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results